Polymorphisms of the subunits of the NMDA receptor (N-methyl-D-aspartate) seem to determine alteration of the cortical activity linked to basic cognitive functions. It is to hope that this may represent a new biological marker to be used in the near future for preclinical screening and tailored therapies across neurodevelopmental disorders.
NMDA (N-Metil-D-Aspartate) receptor subunits polymorphisms, which determine a signaling dysfunction, seem to represent a molecular substrate common to different neuropsychiatric developmental disorders.
In people with intellectual disability, sleep disorders are very frequent. What factors have been considered to explain such a high prevalence? Are these disorders underpinned by wider psychiatric disorders?
In some cases, symptoms and dysfunctions of autism spectrum disorders can be confused with those of other psychiatric disorders. In other cases it seems more appropriate to speak of a diagnostics shadowing. Autistic polymorphism or comorbidity? How to evaluate?